The market loves to put things in neat little boxes, but what happens to the leftovers? You get a Frankenstein’s monster of a portfolio. This is stupid and here's why. Sweeping everything from a failing gene therapy firm to a 2x leveraged Reddit ETF into the same thematic bucket tells you exactly how unmoored the 2026 market really is. Are we actually analyzing businesses here, or just blindly throwing darts at a board?

Let's start with Freshworks (FRSH.US). It took them long enough, but they finally delivered their first GAAP-profitable quarter in Q2 2026, raking in USD 237.4 million in revenue and even raising their full-year guidance. It’s about time a SaaS company actually proved it can make money instead of just burning it. As for the rest of this group? Good luck with that.

Look at Cinemark (CNK.US). They just crossed the USD 1 billion revenue mark in Q2 2026, entirely bailed out by Spider-Man saving the domestic box office. Relying on Hollywood’s weekend hits is a 20th-century business model desperately trying to survive the streaming era, but hey, it worked this time. Meanwhile, GraniteShares 2x Long RDDT Daily ETF (RDTL.US) is pure, unadulterated speculation. A leveraged ETF on a meme-heavy internet forum? Because regular volatility just wasn’t dangerous enough.

In the tech and space sector, Mobix Labs (MOBX.US) is busy rebranding to NSM Labs and acquiring a drone maker for USD 15 million. Slapping together buzzwords like "aerospace" and "critical minerals" feels like a desperate attempt to stay relevant. Spire Global (CURR.US) managed to scrape together a USD 3 million NOAA contract extension for satellite data. My question is: Why aren't you moving faster in a space race that demands aggressive scaling?

The biotech and real estate corners of this portfolio are just grim. Sagimet Biosciences (SAGT.US) burned through USD 14 million in Q2, though they claim their USD 257.6 million cash pile will last until 2028 for their acne drug trials. Passage Bio (PASW.US)? They completely surrendered. After slashing 75% of their workforce, they are limping into an all-stock reverse merger with Remix Therapeutics. Office real estate is equally tragic: Creative Media & Community Trust (CMCT.US) is desperately enacting 1-for-10 reverse stock splits and selling off its lending division after a brutal Q1 loss.

And then there's Gulf Resources (GURE.US). A China-based chemical manufacturer getting Nasdaq delinquency notices for late filings. The stock recently managed a single-day bump of nearly 4% on stable oil export news, but the governance mess is a classic OTC-adjacent nightmare.

The truth is, this grab-bag group perfectly highlights the brutal divide of 2026: a few are finally figuring out how to swim, and the rest are just looking for a piece of debris to hold onto.

This article does not constitute investment advice.